HLA-E and plasma cell myeloma: Our findings are consistent with those of previous studies showing that disruption of NKG2A, by protein expression blockers or CRISPR/Cas9, results in improved antitumor activity of NK cells against HLA-E+ Ewing sarcoma and multiple myeloma, respectively (5, 22).